Aly-Khan Lalani

@lalaniMD

GU Medical Oncologist, | Assistant Professor, I Visiting Scientist, . Views = my own, RT ≠ E.

Vrijeme pridruživanja: veljača 2011.

Tweetovi

Blokirali ste korisnika/cu @lalaniMD

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @lalaniMD

  1. Prikvačeni tweet
    8. sij

    Thank you for the opportunity to serve as Guest Editor for this issue of -- made possible by 💪contributions from insightful colleagues: " for Urinary & Rare Cancers" Editorial: (1/2..)

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 15 sati
    Poništi
  3. prije 15 sati

    Our CYTOSHRINK trial is now open! Nice to see first-patient randomized today, . Thank you to our 💪 multi-D collaborative team and, most importantly, patients & their families. A.Swaminath et al.

    , , i još njih 6
    Poništi
  4. proslijedio/la je Tweet
    prije 23 sata

    Congrats to Dr. Tannir for receiving the Distinguished Clinical Faculty Mentor award. Inspiring acceptance speech on the importance of mentorship!

    , , i još njih 6
    Poništi
  5. proslijedio/la je Tweet
    26. sij

    Continuing to move the game forward . Much respect my brother 💪🏾 #33644

    Poništi
  6. proslijedio/la je Tweet
    8. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Thank YOU for inviting us! Great honor and a big pleasure!

    Poništi
  7. proslijedio/la je Tweet
    8. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Very nice work!

    Poništi
  8. proslijedio/la je Tweet
    8. sij
    Poništi
  9. proslijedio/la je Tweet
    8. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Thank you for your outstanding contribution as guest editor for ! Certainly one of our best issues!

    Poništi
  10. proslijedio/la je Tweet
    8. sij
    Poništi
  11. proslijedio/la je Tweet
    8. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    I totally agree w It’s not only a pleasure but a great honor Thanks !

    Poništi
  12. proslijedio/la je Tweet
    8. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    It’s was our pleasure to be able to contribute!

    Poništi
  13. proslijedio/la je Tweet
    8. sij

    Now Pembrolizumab approved in non-muscle invasive high-risk bladder cancer. First PD1 inh In this space ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦

    Poništi
  14. 8. sij
    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet
    7. sij

    The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff who have made this initiative possible. A few thoughts on what we have learned.

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet
    6. sij

    Press release states this first line maintenance study achieves OS in the ITT population (cisplatin eligable and inelgable) and is therefore distinct from front line atezo/pembro which are currently limited to biomarker positive cisplatin ineligable.

    Poništi
  17. proslijedio/la je Tweet
    2. sij

    My Top 10 GU Onc clinical advances/stories in 2019: RCC: 1) IO/VEGF: Pembro + Axi @ Ave + Axi (), approval 2) IO role in sarcomatoid RCC and pembro role in non-clear cell RCC (KYN-427B), see poster disc session

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    2. sij
    Poništi
  19. proslijedio/la je Tweet
    26. pro 2019.

    This Viewpoint highlights current applications of science to human health and examines successes and remaining challenges

    Poništi
  20. proslijedio/la je Tweet

    How ironic for to publish a systematic review on time-restricting eating and fasting for by de Cabo and Mattson

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·